Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Has Consensus Price Target of $8.75 According to Analysts

Key Points

• Analysts have a Moderate Buy consensus on Alpha Teknova, with four buy, one hold and one sell rating; the average 12-month price target is $8.75.
• The company reported quarterly revenue of $12.70 million and a loss of $0.06 per share, beating analyst estimates of $11.71 million in revenue and a $0.07 loss per share.
• TKNO opened at $7.88, within its one-year range of $1.91 to $9.48; institutional investors own 13.81% of the stock.

Alpha Teknova, Inc. (NASDAQ:TKNO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $8.75.

Several equities analysts have commented on the stock. BTIG Research raised shares of Alpha Teknova from a "neutral" rating to a "buy" rating and set a $8.00 target price on the stock in a research note on Tuesday, August 11th. Roth Capital initiated coverage on shares of Alpha Teknova in a research note on Wednesday, August 5th. They issued a "buy" rating and a $7.00 price target for the company. Wall Street Zen upgraded shares of Alpha Teknova from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Jefferies Financial Group initiated coverage on shares of Alpha Teknova in a research note on Thursday, September 17th. They set a "buy" rating and a $9.00 price objective on the stock. Finally, Zacks Research upgraded shares of Alpha Teknova to a "hold" rating in a research note on Thursday, August 6th.

Hedge Funds Weigh In On Alpha Teknova

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Alpha Teknova in the second quarter valued at $4,997,000. Bank of America Corp DE bought a new position in Alpha Teknova during the second quarter valued at about $1,453,000. Bank of New York Mellon Corp acquired a new position in Alpha Teknova during the second quarter worth about $604,000. Roubaix Capital LLC grew its holdings in Alpha Teknova by 88.5% during the first quarter. Roubaix Capital LLC now owns 1,882,355 shares of the company's stock worth $5,440,000 after acquiring an additional 883,823 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in Alpha Teknova during the second quarter worth about $115,000. 13.81% of the stock is owned by institutional investors.

Alpha Teknova Trading Up 6.9%

NASDAQ:TKNO opened at $7.88 on Friday. Alpha Teknova has a 1 year low of $1.91 and a 1 year high of $9.48. The stock has a market cap of $423.16 million, a price-to-earnings ratio of -27.17 and a beta of 0.96. The business has a fifty day moving average of $7.72 and a 200-day moving average of $4.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.48 and a current ratio of 4.49.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $12.70 million for the quarter, compared to analysts' expectations of $11.71 million. Alpha Teknova had a negative net margin of 34.76% and a negative return on equity of 24.41%. Equities analysts predict that Alpha Teknova will post -0.28 earnings per share for the current year.

About Alpha Teknova

Alpha Teknova, Inc is a life sciences company that develops and manufactures critical reagents and other products used in biomedical research, biopharmaceutical development and advanced therapies. The company provides laboratory and production materials designed to support applications including cell and gene therapy, molecular diagnostics, next-generation sequencing, vaccine development and pharmaceutical manufacturing.

Its offerings include research-use-only and current Good Manufacturing Practice (cGMP) reagents, buffers, media and other custom-formulated solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.